CN1566086A - Amino acid calcium chelate, preparation and application thereof - Google Patents
Amino acid calcium chelate, preparation and application thereof Download PDFInfo
- Publication number
- CN1566086A CN1566086A CN 03137615 CN03137615A CN1566086A CN 1566086 A CN1566086 A CN 1566086A CN 03137615 CN03137615 CN 03137615 CN 03137615 A CN03137615 A CN 03137615A CN 1566086 A CN1566086 A CN 1566086A
- Authority
- CN
- China
- Prior art keywords
- calcium
- amino acid
- glycine
- mol ratio
- carbaminothioic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Amino acid calcium chelate Chemical class 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000011575 calcium Substances 0.000 claims abstract description 119
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 118
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 104
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 96
- 150000001413 amino acids Chemical class 0.000 claims abstract description 76
- 239000003446 ligand Substances 0.000 claims abstract description 26
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 19
- 229940100691 oral capsule Drugs 0.000 claims abstract description 7
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 58
- 229940106635 calcium amino acid chelate Drugs 0.000 claims description 55
- 239000004471 Glycine Substances 0.000 claims description 47
- 239000002253 acid Substances 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 14
- 229960004452 methionine Drugs 0.000 claims description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 12
- 239000001110 calcium chloride Substances 0.000 claims description 12
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229930182817 methionine Natural products 0.000 claims description 12
- 206010006956 Calcium deficiency Diseases 0.000 claims description 10
- 230000035935 pregnancy Effects 0.000 claims description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000292 calcium oxide Substances 0.000 claims description 6
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 229930182818 D-methionine Natural products 0.000 claims description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
- 229930195722 L-methionine Natural products 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 3
- 125000000296 D-methionine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])SC([H])([H])[H] 0.000 claims 1
- 238000010276 construction Methods 0.000 abstract 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 abstract 1
- 235000019345 sodium thiosulphate Nutrition 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 94
- 235000001014 amino acid Nutrition 0.000 description 61
- 229910021645 metal ion Inorganic materials 0.000 description 23
- 229910052751 metal Inorganic materials 0.000 description 21
- 239000002184 metal Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 239000013522 chelant Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 description 11
- 240000005373 Panax quinquefolius Species 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000037182 bone density Effects 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 206010070538 Gestational hypertension Diseases 0.000 description 6
- 201000005624 HELLP Syndrome Diseases 0.000 description 6
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 6
- 208000030941 fetal growth restriction Diseases 0.000 description 6
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108010048734 sclerotin Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 3
- 206010070531 Foetal growth restriction Diseases 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 229940043430 calcium compound Drugs 0.000 description 3
- 150000001674 calcium compounds Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 231100000001 growth retardation Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 210000001699 lower leg Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 108010063312 Metalloproteins Proteins 0.000 description 2
- 102000010750 Metalloproteins Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940047608 chelated magnesium Drugs 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000001981 hip bone Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000009593 intrauterine fetal growth Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108010080437 Calsequestrin Chemical class 0.000 description 1
- 102000000161 Calsequestrin Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005905 Hydrolysed protein Substances 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an amino acid chelated calcium, wherein the construction contains calcium ions chelated by amino acid ligand, and amino acid ligand comprising glycin and sodium hyposulfite. The invention also relates to the oral capsule form of the amino acid chelated calcium and the use of the amino acid chelated calcium.
Description
Technical field
The present invention relates to a kind of calcium amino acid chelate and preparation thereof and application, relate to a kind of specifically with calcium amino acid chelate and preparation and the application of glycine and carbaminothioic acid as part.
Technical background
At present, amino-acid chelate generally is the stable heterocycle structure of metal ion reaction generation by a-amino acid and positive divalence (or higher).In such reaction, the positive charge of metal ion by carboxyl in the a-amino acid or amino with the lone-pair electron neutralization.
Usually, the traditional definition of inner complex is the heterocycle structure that metal ion forms by chemical bond and one or more part.According to this definition, inner complex is by the electric charge of the metal ion of ionic linkage, covalent linkage or coordinate bond neutral zone divalence positive charge.In modern relatively definition, inner complex is that metal ion is by the ring texture of coordinate bond with the part formation of band lone-pair electron.In a word, inner complex is the heterocycle structure that metal ion and part form.
The conditional decision of the structure of inner complex when synthetic.Chelatropic reaction must carry out under suitable condition, particularly in the definition in modern times.These suitable conditions comprise the molar ratio of part and metal ion, pH value of aqueous solution and dissolubility of reactants during reaction.Usually, reactants dissolved in solution, is arranged the generation chelatropic reaction with ionic state or suitable electronics, between part and metal ion, form coordinate bond and/or ionic linkage.
By the displacement of chemical bond in the infrared spectra relatively or by the spectral absorption band that chemical bond causes, can confirm the inner complex that generates inner complex and other mixture to be made a distinction simultaneously.Aspect the supply mineral nutrition, there are two kinds of chelating products often to use.A kind of is metalloprotein salt, and U.S. food management association defines the result that this product is amino acid whose soluble salt and partially hydrolysed protein generation sequestering action.This is a kind of special metalloprotein salt, as cuproprotein salt, calsequestrin salt etc.
The definition of amino-acid chelate that U.S. food management association is also clear and definite.Amino-acid chelate is that metal ion in the soluble metal salt and amino acid reaction generate, 1 mole metal ion and 1-3 in this reaction (preferably 2) mole amino acid formation coordinate bond.The molar mass of hydrolysis amino acid will be near 150, and the molar mass that reaction generates inner complex can not surpass 800.Such material is exactly an inner complex, as iron-amino acid chelate, copper amino acid chelate, calcium amino acid chelate etc.
By correct method synthetic amino-acid chelate is a kind of stable compound, and wherein the Sauerstoffatom of carboxyl and alpha-amino group form one or more five-membered ring structures in metal ion and the a-amino acid.Such five-membered ring structure is made of the Sauerstoffatom of atoms metal, carboxyl, carbon atom, alpha-carbon atom and the alpha-amino nitrogen-atoms of carboxyl.The molar ratio of this structure and part and metal, the Sauerstoffatom of carboxyl whether form coordinate bond with metal ion or ionic linkage relevant.Usually, the molar ratio of part and metal is 1: 1 at least, and optimum proportion is 2: 1; But under given conditions, can reach 3: 1, even 4: 1.Typical case's representative: the ratio of part and metal is 2: 1 in the amino-acid chelate
Wherein, M representation metal ion.
In above-mentioned chemical formula, dotted line is represented coordinate bond, covalent linkage or ionic linkage; Solid line is represented covalent linkage or coordinate bond (that is: the chemical bond between metal and alpha-amino group).When the R substituting group was H, amino acid was glycine, was the simplest amino acid of structure.R also can be the substituting group of other 20 multiple amino acids or other amino acid whose substituting groups that proteolysis produces.When R is-CH
2-CH
2-S-CH
3The time, carbaminothioic acid is a methionine(Met); When R is-CH
2During-SH, carbaminothioic acid is a halfcystine.And bimolecular half Guang ammonia and disulfides other than hydrogen reaction generate Gelucystine.Though side chain is different, the Sauerstoffatom of carboxyl has identical arrangement with alpha-amino nitrogen-atoms in all amino acid, all can be in having an effect with metal ion.In other words, there is identical atomic building in the chelate ring in the different compound.
The metal of oxidation state forms chemical bond by sequestering action.For example: the nitrogen-atoms in the amino acid whose alpha-amino group provides and forms the electronics of chemical bond in required, and these electronics occupy metal ion d track and form coordinate bond.Therefore ,-metal ion of individual positive divalence can form four chemical bonds by sequestering action.Like this, reach electrobalance in the inner complex, the electric charge of atoms metal was zero (comprising that whole minute charge of the electron also is zero).By former theory, metal ion can form coordinate bond or ionic linkage with the Sauerstoffatom of carboxyl.But in fact, metal ion only forms coordinate bond with amino acid whose alpha-amino group.
The structure of amino-acid chelate, chemical property and biological activity are all on the books in the literature.For example: " chelating mineral nutrition " (1982) Chas.C.Thomas distribution of work such as Ashmead; Work such as Ashmead " intestinal absorption of metal ion " (1985) Chas.C.Thomas distribution; Works such as Ashmead " the edible base of leaf plant that contains amino-acid chelate " (1986) Noyes publishes; U.S. Patent number is 4,020,158; 4,167,564; 4,216,143; 4,216,144; 4,599,152; 4,774,089; 4,830,716; 4,863,898 etc.And the enhancing stimulant that contains vitamin b6 usp and amino-acid chelate has obtained United States Patent (USP), the patent No. 4,725,427.
On the one hand, in the mineral nutrition field, amino-acid chelate can be as common amino acid by small intestine epithelium mucomembranous cell in the animal body or vegetable cell active absorption.On the other hand, in the trophic structure of animal, the mineral substance in the amino-acid chelate is that carrier is by active absorption with amino acid.Therefore, ionic activity competition for space and the active associated problem of inhibition certain minerals nutritive substance have effectively been avoided.
Calcium is the maximum a kind of inorganic elements of content in the human body, and second messenger's title is arranged.Generally speaking, become human body to include the calcium total amount and be about 1200 grams.Wherein about 99% concentrates in bone and the tooth, and all the other are present in extracellular fluid, blood and the soft tissue 1% often with free or bonded ionic condition.The grownup has 700 milligrams calcium to upgrade every day approximately, therefore must absorb calcium from food.Calcium ion is normally beaten for heart, and keeping and pair cell membrane permeability, the activation of being permitted plurality of enzymes of the conduction of the solidifying of blood, muscle and neural NE, suitable irritability all plays an important role, and lacks then can cause multiple disease.Calcium contents reduces in the body fluid, and capillary permeability strengthens, and the composition in the blood can ooze out outside the blood vessel, the pathogenesis of some anaphylactic disease that Here it is.Blood calcium concentration is low when per 100 milliliters of blood are below 7 milligrams, and neural skeletal muscle excitability strengthens, and tetany or convulsions can occur.Calcium and Skeletal Muscle Contraction in the sarcoplasm have direct relation, and the normal contraction of keeping cardiac muscle is also played an important role.If calcium concn is too high, can weaken musculartone, cause bradycardia or cardiac arrest.It is reported that the Gestation period is because the needs of embryo growth and development, parent increases the requirement of calcium, but the pregnancy period is because the variation of Q volume of blood increases the UCaE amount, and estrogenic rising of pregnancy period has suppressed the absorption of parent to bone calcium again to a certain extent, therefore be in low calcium state in pregnant woman's body, should be 1000-1200mg for keeping calcium level calcium pickup amount, it is 1200-1600mg/ days that health ministry is recommended the intake of pregnant woman and lactating women's calcium every day.And these calcareous all should be by absorbing in the food.Because the meals of China are based on the food in vegetalitas source, milk-product are less, so the calcium absorption amount is lower in the meals, need suitable supplement calcium to satisfy Gestation period demand.When in pregnant woman's body during the calcium insufficiency of intake, at first to satisfy the needs of fetus, disregard and mobilize pregnant woman's bone calcium to store and the bone calcium depletion.Occur thus a series of calcium deficiency and osteoporotic clinical manifestation as, pregnancy induced hypertension syndrome (pregnancyind-hypertension, PIH) and the fetal in utero growth retardation (intrauterinefetal growth retardation, IUGR).Comparative study is the result show, be 7.5% from the pregnant 20 pregnant woman's phase pregnancy induced hypertension syndrome sickness rate that replenish 2g calcium every day in week, and control group is 16.5%, significant difference.Simultaneously pregnancy induced hypertension syndrome is the one of the main reasons of fetal intrauterine growth retardation, during general gestation IUGR send out that to examine rate be 2.75-4.9%, and can be during pregnancy induced hypertension syndrome up to 10.5%-35.0%.Replenish the calcium agent and can improve the bone density of human body and losing of prevention bone effectively.
Based on existing technology, synthetic a kind of than existing inorganic calcium compound more stable, have more that the organic calcium compound of strong biological activity is very important.And, synthetic a kind of calcium containing compound that contains calcium ion, glycine and carbaminothioic acid that forms by sequestering action, make in the compound mass ratio of calcium be easy to control, can make calcium can satisfy vast clinical demand more simultaneously easily by specific tissue and organ utilization.
Summary of the invention
The object of the present invention is to provide a kind of different aminoacids that contains, promptly the molar ratio of the amino acid ligand of glycine and carbaminothioic acid and calcium metal is 1: 1-2: 1 calcium amino acid chelate.
Another object of the present invention is to provide the pharmaceutical preparation such as the oral capsule of above-mentioned chelating amino acids calcium cpd.
The present invention also aims to be used for the treatment of calcium deficiency prevention fracture and replenishing the calcium to pregnant women for the human or animal provides a kind of calcareous material stable, high biological activity.
The object of the present invention is achieved like this:
A kind of calcium amino acid chelate, comprise in its structure by the calcium ion of amino acid ligand chelating and the amino acid ligand formed by glycine and carbaminothioic acid, it is characterized in that it reacts generation by calcium containing compound, carbaminothioic acid and glycine in the aqueous solution, wherein the mass percent of calcium is 12～50%, the mol ratio of amino acid ligand and calcium ion is 1: 1-2: 1, and the mol ratio of glycine and carbaminothioic acid is 1 in the amino acid ligand: 6-6: 1.
In the present invention, inner complex refers to the heterogeneous ring compound that metal ion and part form by chemical bond.Sauerstoffatom in the carboxyl may form coordinate bond, covalent linkage or ionic linkage.But alpha-amino group can only form typical coordinate bond.
Amino acid ligand can mix before the reaction of two seed amino acids and calcium ion, or mixed when reacting with calcium ion, also can a seed amino acid with add another kind of amino acid again after calcium ion reacts and mix reaction.
In the present invention, carbaminothioic acid preferred methionine(Met), halfcystine or Gelucystine.Most preferably D-methionine(Met), L-methionine(Met) or their mixture.
In the present invention, calcium containing compound preferably calcium chloride, calcium oxide or their mixture.Calcium chloride most preferably.
Further, in the present invention, the amino acid ligand of calcium amino acid chelate and the mol ratio of calcium ion are 2: 1.
The part of above-mentioned calcium amino acid chelate and the mol ratio of calcium ion are 2: 1 o'clock, and wherein the mass percent of calcium preferably 15～30%, most preferably 18～27%.
The part of above-mentioned calcium amino acid chelate and the mol ratio of calcium ion are 2: 1 o'clock, wherein in the amino acid ligand mol ratio of glycine and carbaminothioic acid be preferably 2: 3～6: 1, more preferably 5: 4～5: 2, most preferred was 5: 4 or 5: 2.
Same, in the present invention, the amino acid ligand of calcium amino acid chelate and the mol ratio of calcium ion are 1: 1.
The part of above-mentioned calcium amino acid chelate and the mol ratio of calcium ion are 1: 1 o'clock, and wherein the mass percent of calcium preferably 24～47%, most preferably 30～44%.
The part of above-mentioned calcium amino acid chelate and the mol ratio of calcium ion are 1: 1 o'clock, wherein in the amino acid ligand mol ratio of glycine and carbaminothioic acid be preferably 2: 3～6: 1, more preferably 5: 4～5: 2, most preferredly be 5: 4 or be 5: 2.
A kind of calcium amino acid chelate oral capsule, said preparation is with calcium amino acid chelate and vitamins D
3For main active ingredient is prepared from.Vitamins D wherein
3Can promote absorption and the utilization of human body to calcium.
A kind of calcium amino acid chelate is as the calcium deficiency therapeutical agent of effective constituent.Use calcium amino acid chelate can satisfy the demand of life entity, thereby guarantee its sound development calcium.
The pregnancy period syndrome therapeutical agent that a kind of calcium amino acid chelate causes as the calcium deficiency of effective constituent.Calcium amino acid chelate can all dissolve in the intestinal fluid of alkalescence, participates in the Epithelium of intestinal villus cell amino acid whose active transport process is absorbed fully, has improved the absorption and the utilization of calcium.Improve the human body biochemical indicator, alleviate clinical symptom.
The present invention compared with prior art, calcium amino acid chelate is calcium and amino acid synthetic organic calcium compound, its Stability Analysis of Structures, biological activity and bioavailability height very easily are absorbed by the body, specific absorption is up to more than 90%.It uses the part of multiple amino acids as amino-acid chelate, because different amino acid whose molecular weight differences increases or reduce the mass percent that amino acid can be adjusted metal ion.For example, wish that the mass percent of metal ion is higher, can improve the usage quantity (glycine is the amino acid of molecular weight minimum) of glycine in the reaction, and select less carbaminothioic acid of molecular weight such as halfcystine simultaneously.If wish that the mass percent of metal ion is lower, can reduce the usage quantity of glycine in the reaction.In addition, concerning calcium ion, use carbaminothioic acid also to have certain advantage as part.These advantages are 4,863,898 in the patent No., United States Patent (USP) on the books, all theories all confirm on evidence.Wherein particularly methionine(Met) helps the health of wound, reproductive organ, liver, and halfcystine is useful to the brain reflex action.Because calcium has nervimuscular excitatoty promotion function, have the part of the carbaminothioic acid of above-mentioned functions so use as part, be very valuable to entire compound.Calcium amino acid chelate of the present invention is mainly used in the treatment calcium deficiency, and can prevent to fracture and to the replenishing the calcium of pregnant women, and has no side effect.Be a kind of safety, the medicine of effectively replenishing the calcium.
Embodiment
Further specify the present invention below in conjunction with embodiment
Embodiment 1
Calcium amino acid chelate is to the effect of supplemented calcium of rat: add 3000mg/kg in beverage, can significantly increase body weight and the height of rat; Calcium intake between metabilic stage is significantly higher than the calcium deficiency group, and calcium retains rate and also is higher than the calcium deficiency group, and can significantly improve the calcium level in plasma calcium and the spleen, and can obviously increase rat femur content of mineral substances and bone density.Find simultaneously after one week that the Cu content in the tissue is 5 times of control group.Because calcium amino acid chelate continues to dissociate in blood plasma, form one in vivo and release the calcium cycle for a long time, so can improve the absorption and the effect of tissue to calcium.
Embodiment 2
Select the healthy people in 96 35-55 years, be divided into 3 groups at random, the A group is taken calcium amino acid chelate, the B group is taken calglucon, the C group is taken the tracking test that placebo has carried out 36 months, measured lumbar vertebrae and cervical vertebra density and serum alkaline phosphatase at the 3rd, 6,12,18,24,36 month, the result is as follows:
(1) clinical experiment condition table:
| Experiment condition | A group/32 | B group/32 | C group/32 |
| Man/woman | 7/25 | 7/25 | 7/25 |
| Mean age | 46.2 | 45.6 | 47.1 |
| Every day dosage | Chelating calcium 500mg | Calglucon 500mg | 0 |
| VD3 | 200.IU | 200.IU | 0 |
(2) bone density (BMD) improves counting rate meter after the clinical experiment
| Category | Lumbar vertebrae | Cervical vertebra |
| The A group | 85％ | 55％ |
| The B group | 40％ | 27％ |
| The C group | Do not have | Do not have |
Conclusion: clinical effectiveness demonstrates additional calcium agent can improve the bone density of human body and losing of prevention bone effectively, and different calcium agent has different bioavailabilities: wherein the calcium amino acid chelate curative effect is better.
Embodiment 3
With 50-70 year, climacteric is above 241 of the women more than 10 years, exclude 196 experimenters behind the people of medicine who takes oestrogenic hormon, steroid hormone, anticonvulsant drug, thiazine hydragog(ue) or other and influence calcium metabolism, check UP, health consultation, biochemical test, sclerotin scanning and inquired their daily daily life diet and physical activity situation after; Chosen 168 women and studied,, be divided into 4 groups at random according to lot.1 group: 42, take before sleeping every day and contain the 1g calcium amino acid chelate.2 groups: 42, take placebo before sleeping.3 groups: 42, be the exercise group, remove and take outside 1 gram chelating calcium and their every day of the normal exercise, per week also needs to increase by 4 hours amount of exercise.Wherein two hours is controlled exercise, and 1 hour based on weight training.The trier also required the per week walking 2 hours.In these exercise processes,, require them should reach the amount of exercise that improves heart rate 60% according to their age.4 groups: 42, the milk powder group is taken the milk powder of 536-778 milligram every day.The bone density of sclerotin and neck of femur sclerotin, far-end anklebone matter between their lumbar vertebrae of results of regular determination and hipbone rotor sclerotin, rotor, and regularly collect each experimenter's urina sanguinis sample, blood sample and 24 hours urine sample, analyze creatinine slurry, alkaline phosphatase and ionized calcium value in creatinine, calcium and phosphoric acid, oxyproline value and the blood in the urine, study.Through the tracing observation in 2 years, the result was as follows:
One, different skeleton position bone mineral rate of change of the density (%/year)
| Test group | The rotor position | The internal rotor position | Thigh neck position | Far-end ankle joint position |
| Placebo | -0.85±0.33 | -0.81±0.26 | -0.67±0.21 | -2.47±0.24 |
| The inner complex group | +0.50±0.23 | +0.17±0.21 | -0.18±0.20 | -1.65±0.23 |
| Chelating calcium adds the physical activity group | +0.81±0.41 | +0.23±0.32 | +0.28±0.34 | -1.05±0.41 |
| The milk powder group | ?+0.24±0.26 | ?+0.07±0.26 | ?-0.18±0.24 | ?-1.51±0.22 |
| Compare P＜0.05 and calcium tablet group comparison+P＜0.05 with placebo | ||||
From above data as can be seen: except that neck bone density and ionized calcium, the most cases in four groups has compliance.And the absorption effect difference of different calcium, the bone density of the group of not replenishing the calcium reduces significantly, and the milk powder group and the calcium tablet group of replenishing the 536-778 milligram in every day in December there are not difference, but exercise group effect is good significantly, the growth of the bone density of some sclerotin nearly 10%.Can both effectively prevent and treat the bone loss of between hipbone, rotor bone, rotor bone no matter be to replenish calcium with chelating calcium tablet or milk powder form every day, but be not clearly to distal tibia.
Embodiment 4
One, data and method:
(1) object: be pregnant and lying-in women just, age 23-37 year, 27.38 years old mean age, in pregnant 14-28 week, have clinical symptom such as shank spasm, numb limbs and tense tendons or waist and sacrum pain and low blood calcium person totally 132 examples.
(2) method: the patient is divided into two groups at random, treatment group Moriamin Forte chelating calcium 1g every day; Control group oral calcium gluconate oral liquid (Harbin No.3 Pharmaceutical Factory production, 1g/ props up, different lot numbers are some) 3 times on the 1st, 1 time 1, add the vitamin AD capsule and pill simultaneously, 1 of every day.1 month was 1 course of treatment, treatment expiration back check.
(3) therapeutic evaluation produce effects: biochemical indicator recovers normal or near normal, clinical symptom disappears substantially.Effectively: clinical symptom relief, blood biochemistry index take a turn for the better.Invalid: clinical symptom, blood biochemistry index change little or do not have change.Respectively organize clinical symptom before the treatment and biochemical situation sees Table 1, table 2.
Respectively organize biochemical values (s ± x) before table 1 treatment
| Group | Blood calcium value (mmol/L) | Serium inorganic phosphorus value (mmol/L) |
| The treatment group | 1.894±0.093 | 1.261±0.0249 |
| Control group | 1.900±0.057 | 1.286±0.199 |
| Normal value | 2.1-2.6 | 0.80-1.55 |
Respectively organizing clinical symptom before table 2 treatment distributes
| Group | Numb limbs and tense tendons (example) | Shank spasm (example) | Lumbus sacrum pain | Add up to |
| The treatment group | 27 | 11 | 21 | 59 |
| Control group | 13 | 8 | 11 | 32 |
Two, result
(1) the biochemical performance of blood: treat and respectively organize blood biochemistry after 1 month and the results are shown in Table 3
Respectively organize biochemical result (s ± x) after table 3 treatment
| The treatment group | Control group | P | ||
| Blood calcium | Before the treatment | 1.894±0.093 | 1.900±0.057 | ＜0.01 |
| After the treatment | 2.350±0.173 | 2.143±0.116 | ||
| Serium inorganic phosphorus | Before the treatment | 1.261±0.249 | 1.286±0.199 | ＜0.05 |
| After the treatment | 1.328±0.216 | 1.221±0.204 |
By finding out in the table: variation in various degree all took place in the blood calcium value after treatment group and control group were taken medicine, and comparing with each group before the treatment all has significant difference (P＜0.01).And the blood calcium value of the blood calcium value after treatment group and the treatment of control group and two groups of treatment front and back is learned processing by statistics, and very significant difference (P＜0.01) is more arranged between two groups, illustrates that the degree of treatment group raising blood calcium significantly is better than control group.
Variation in various degree all takes place in the back serium inorganic phosphorus value of taking medicine treatment group and control group, treatment group serium inorganic phosphorus value slightly raises, control group then reduces, compare and significant difference is all arranged (P＜0.05) with each group before the treatment, illustrate that the capsular while of calcium amino acid chelate can improve the serium inorganic phosphorus level, can be used for low calcium, low-phosphorous patient.
(2) after treatment group was treated January, symptoms such as clinical symptom such as shank spasm, numb limbs and tense tendons, lumbosacral region slight illness disappeared substantially; And treatment of control group had 8 examples not see and is clearly better after January.
(3) Comparison of therapeutic:
Table 4 is respectively organized Comparison of therapeutic
| Produce effects (example) | Effectively (example) | Effectively (example) | Effectively (example) |
| The treatment group | 47 | 34 | 4 | 95.30 |
| Control group | 18 | 22 | 8 | 88.3 |
P＜0.05
Learn to handle by statistics, two groups have significant difference (P＜0.05) between efficient, the efficient gluconic acid Ca oral liquid group that is significantly higher than of calcium amino acid chelate group are described.
Embodiment 5
The pregnant woman in 240 pregnant 20-24 weeks is carried out the pregnancy period perspective study of replenishing the calcium:
| Group | The example number | Pregnancy induced hypertension syndrome | Fetal intrauterine growth retardation | ||
| n | ％ | n | ％ | ||
| Calcium amino acid chelate | 120 | 8 | 6.6 | 5 | 4.2 |
| Control group | 120 | 32 | 26.6 | 21 | 17.5 |
Clinical test results finds to replenish the calcium the pregnancy period, and that pregnant woman's clinical symptom is improved effect is obvious, reduced pregnancy induced hypertension syndrome (pregnancy ind-hypertension, PIH) and fetal in utero growth retardation (intrauterine fetal growth retardation, incidence IUGR).Calcium amino acid chelate is taken no side reaction appearance in the process simultaneously, takes the pregnant woman and all reflects satisfaction.
Embodiment 6
The calcium amino acid chelate oral capsule:
30 milligrams of calcium amino acid chelates
0.1 milligram of Vitamin D3 500,000 I.U/GM
140 milligrams of soyflours
200 milligrams in ground rice
10 milligrams in barley-sugar dextrin
After, add an amount of dehydrated alcohol wet mixing after, granulate, dry, incapsulate.
Embodiment 7
The calcium amino acid chelate oral capsule:
Calcium amino acid chelate 1050mg
Calcium ascorbate 72mg
Secondary calcium phosphate 55mg
Amino acid chelated magnesium 75mg
Zinc-amino acid chelate 20mg
Copper amino acid chelate 0.5mg
Chelating amino acids manganese 5mg
Chelating amino acids vanadium 0.1mg
Chelating amino acids silicon 3.7mg
Chelating amino acids boron 2mg
Vitamin D3 500,000 I.U/GM 0.1mg
Method for making: after the thorough mixing, incapsulate.
Form inner complex by necessary calcium of human body and various trace elements by coordinate bond and amino acid, be solubility humatite matter, and be aided with vitamins D
3The compound preparation of making, the calcium content height, pH value is near neutral, in acidic gastric juice and alkaline intestinal juice, all can stably dissolve and do not produce precipitation, calcium constituent that it is contained and trace element can make on intestinal villi that the cell active transportation is amino acid whose to be absorbed into blood simultaneously, so have very high specific absorption.
Embodiment 8
The calcium amino acid chelate oral capsule:
Calcium amino acid chelate 523.6mg
Copper amino acid chelate 1.7mg
Calcium ascorbate 145.0mg
Chelating amino acids manganese 8.2mg
Secondary calcium phosphate 110.0mg
Chelating amino acids vanadium 0.1mg
Amino acid chelated magnesium 167.0mg
Chelating amino acids silicon 3.3mg
Zinc-amino acid chelate 40.0mg
Chelating amino acids boron 0.9mg
Vitamins D
3200.0IU
Method for making: after the thorough mixing, incapsulate.
Embodiment 9
29.6 gram calcium chloride, 12 gram methionine(Met) and 30 gram glycine reacted in the aqueous solution of temperature 140-150 degree Celsius after 60 minutes, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 2: 1, and the Theoretical Mass per-cent of calcium is 20.0%, and the mol ratio of glycine and methionine(Met) is about 5: 2.Because sulfate radical is arranged, the mass percent that records calcium is 15.2%.
Embodiment 10
29.6 gram calcium chloride, 19 gram halfcystines and 23 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius.Wherein the mol ratio of part and metal is about 2: 1, and the Theoretical Mass per-cent of calcium is 19.4%, and the mol ratio of glycine and halfcystine is about 5: 4.Because sulfate radical is arranged, the mass percent that records calcium is 14.8%.
Embodiment 11
14.9 gram calcium oxide, 40 gram Gelucystines and 20 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 2: 1, and the Theoretical Mass per-cent of calcium is 18.4%, and the mol ratio of glycine and Gelucystine is about 1: 1.Because sulfate radical is arranged, record the mass percent 14.1% of calcium.
Embodiment 12
29.6 gram calcium chloride, 31 gram halfcystines and 18 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 2: 1, and the Theoretical Mass per-cent of calcium is 19%, and the mol ratio of glycine and halfcystine is about 2: 3.Because sulfate radical is arranged, the mass percent that records calcium is 16%.
Embodiment 13
14.9 gram calcium oxide, 62 gram methionine(Met) and 3 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 2: 1, and the mol ratio of glycine and methionine(Met) is about 1: 6, and the mass percent that records calcium is 10%.
Embodiment 14
29.6 gram calcium chloride, 3 gram Gelucystines and 18 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 1: 1, and the Theoretical Mass per-cent of calcium is 41.2%, and the mol ratio of glycine and Gelucystine is about 6: 1.Because sulfate radical is arranged, the mass percent that records calcium is 27%.
Embodiment 15
29.6 gram calcium chloride, 6 gram methionine(Met) and 15 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 1: 1, and the Theoretical Mass per-cent of calcium is 39.4%, and the mol ratio of glycine and methionine(Met) is about 5: 2.Because sulfate radical is arranged, the mass percent that records calcium is 22%.
Embodiment 16
29.6 gram calcium chloride, 9 gram halfcystines and 11 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 1: 1, and the mass percent of calcium is 23.5%, and the mol ratio of glycine and halfcystine is about 5: 4.
Embodiment 17
14.9 gram calcium oxide, 20 gram Gelucystines and 10 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 1: 1, and the mol ratio of glycine and Gelucystine is about 1: 1, and records the mass percent 25% of calcium.
Embodiment 18
29.6 gram calcium chloride, 15 gram halfcystines and 9 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 1: 1, and the Theoretical Mass per-cent of calcium is 36%, and the mol ratio of glycine and halfcystine is about 2: 3.Because the existence of sulfate radical is arranged, the mass percent that records calcium is 20.9%.
Embodiment 19
14.9 gram calcium oxide, 31 gram methionine(Met) and 1 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 1: 1, and the mol ratio of glycine and methionine(Met) is about 1: 6, and the mass percent that records calcium is 19%.
Embodiment 20
29.6 gram calcium chloride, 8 gram Gelucystines and 36 gram glycine reacted 60 minutes in the aqueous solution of temperature 140-150 degree Celsius, i.e. a kind of calcium amino acid chelate of Sheng Chenging.Wherein the mol ratio of part and metal is about 2: 1, and the Theoretical Mass per-cent of calcium is 23.1%, and the mol ratio of glycine and Gelucystine is about 6: 1.Because sulfate radical is arranged, the mass percent that records calcium is 17.2%.
Claims (22)
1, a kind of calcium amino acid chelate, comprise in its structure by the calcium ion of amino acid ligand chelating and the amino acid ligand formed by glycine and carbaminothioic acid, it is characterized in that it reacts generation by calcium containing compound, carbaminothioic acid and glycine in the aqueous solution, wherein the mass percent of calcium is 12～44%, the mol ratio of amino acid ligand and calcium ion is 1: 1-2: 1, and the mol ratio of glycine and carbaminothioic acid is 1 in the amino acid ligand: 6-6: 1.
2, a kind of calcium amino acid chelate according to claim 1 is characterized in that carbaminothioic acid is a methionine(Met), halfcystine or Gelucystine.
3, a kind of calcium amino acid chelate according to claim 1 and 2 is characterized in that the carbaminothioic acid in the calcium amino acid chelate is D-methionine(Met), L-methionine(Met) or their mixture.
4, a kind of calcium amino acid chelate according to claim 1 is characterized in that calcium containing compound is calcium chloride, calcium oxide or their mixture.
5,, it is characterized in that calcium containing compound is a calcium chloride according to claim 1 or 4 described a kind of calcium amino acid chelates.
6, according to the described a kind of calcium amino acid chelate of claim 1, the mol ratio that it is characterized in that amino acid ligand and calcium ion is 2: 1.
7, according to claim 1 or 6 described a kind of calcium amino acid chelates, the mass percent that it is characterized in that calcium is 15～30%.
8, according to claim 1 or 6 described a kind of calcium amino acid chelates, the mass percent that it is characterized in that calcium is 18～27%.
9,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 2: 3～6: 1 in the amino acid ligand according to claim 1 or 6 described a kind of calcium amino acid chelates.
10,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 5: 4～5: 2 in the amino acid ligand according to claim 1 or 6 described a kind of calcium amino acid chelates.
11,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 5: 4 in the amino acid ligand according to claim 1 or 6 described a kind of calcium amino acid chelates.
12,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 5: 2 in the amino acid ligand according to claim 1 or 6 described a kind of calcium amino acid chelates.
13, a kind of calcium amino acid chelate according to claim 1, the mol ratio that it is characterized in that amino acid ligand and calcium ion is 1: 1.
14, according to claim 1 or 13 described a kind of calcium amino acid chelates, the mass percent that it is characterized in that calcium is 24～47%.
15, according to claim 1 or 13 described a kind of calcium amino acid chelates, the mass percent that it is characterized in that calcium is 30～44%.
16,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 2: 3～6: 1 in the amino acid ligand according to claim 1 or 13 described a kind of calcium amino acid chelates.
17,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 5: 4～5: 2 in the amino acid ligand according to claim 1 or 13 described a kind of calcium amino acid chelates.
18,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 5: 4 in the amino acid ligand according to claim 1 or 13 described a kind of calcium amino acid chelates.
19,, it is characterized in that the mol ratio of glycine and carbaminothioic acid is 5: 2 in the amino acid ligand according to claim 1 or 13 described a kind of calcium amino acid chelates.
20, a kind of calcium amino acid chelate oral capsule, said preparation is with calcium amino acid chelate and vitamins D
3For main active ingredient is prepared from.
21, a kind of calcium amino acid chelate is as the calcium deficiency therapeutical agent of effective constituent.
22, the pregnancy period syndrome therapeutical agent that causes as the calcium deficiency of effective constituent of a kind of calcium amino acid chelate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03137615 CN1566086A (en) | 2003-06-18 | 2003-06-18 | Amino acid calcium chelate, preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03137615 CN1566086A (en) | 2003-06-18 | 2003-06-18 | Amino acid calcium chelate, preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1566086A true CN1566086A (en) | 2005-01-19 |
Family
ID=34470475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03137615 Pending CN1566086A (en) | 2003-06-18 | 2003-06-18 | Amino acid calcium chelate, preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1566086A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100486990C (en) * | 2006-07-14 | 2009-05-13 | 中国科学院南海海洋研究所 | Glutathione calcium chelate and its preparing method, use and composition |
| CN103919136A (en) * | 2014-04-29 | 2014-07-16 | 吉林大学 | Methionine chelating calcium tablets and processing method thereof |
| CN105326855A (en) * | 2015-10-27 | 2016-02-17 | 南京大学 | Compound interlayer type chelating magnesium calcium tablet easy to absorb |
| CN106176831A (en) * | 2016-07-21 | 2016-12-07 | 南京正宽医药科技有限公司 | A kind of amino acid chelating calcium capsule and preparation method thereof |
| JP2019182770A (en) * | 2018-04-06 | 2019-10-24 | 株式会社ダイセル | Production method of s-allylcysteine |
| WO2023206055A1 (en) * | 2022-04-26 | 2023-11-02 | 深圳湾实验室 | Modification and use of silk fibroin |
-
2003
- 2003-06-18 CN CN 03137615 patent/CN1566086A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100486990C (en) * | 2006-07-14 | 2009-05-13 | 中国科学院南海海洋研究所 | Glutathione calcium chelate and its preparing method, use and composition |
| CN103919136A (en) * | 2014-04-29 | 2014-07-16 | 吉林大学 | Methionine chelating calcium tablets and processing method thereof |
| CN103919136B (en) * | 2014-04-29 | 2016-07-06 | 吉林大学 | A kind of methionine sequestration calcium tablet and processing method |
| CN105326855A (en) * | 2015-10-27 | 2016-02-17 | 南京大学 | Compound interlayer type chelating magnesium calcium tablet easy to absorb |
| CN106176831A (en) * | 2016-07-21 | 2016-12-07 | 南京正宽医药科技有限公司 | A kind of amino acid chelating calcium capsule and preparation method thereof |
| JP2019182770A (en) * | 2018-04-06 | 2019-10-24 | 株式会社ダイセル | Production method of s-allylcysteine |
| JP2022105586A (en) * | 2018-04-06 | 2022-07-14 | 株式会社ダイセル | Method for producing S-allylcysteine |
| JP7163052B2 (en) | 2018-04-06 | 2022-10-31 | 株式会社ダイセル | Method for producing S-allylcysteine |
| WO2023206055A1 (en) * | 2022-04-26 | 2023-11-02 | 深圳湾实验室 | Modification and use of silk fibroin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7375243B2 (en) | Method for preparation of amino acid chelate | |
| WO2011065864A1 (en) | Biologically active food additive for the prophylaxis of osteoporosis diseases | |
| CN1566086A (en) | Amino acid calcium chelate, preparation and application thereof | |
| CN103848748B (en) | A kind of employing birds, beasts and eggs shell class is that calcium-glutamate chelate and preparation method thereof is prepared in calcium source | |
| CN106075385A (en) | A kind of polypeptide oral liquor and preparation method thereof | |
| CN1519227A (en) | Zine chelated amino acid as well as its preparation and application | |
| Davis et al. | Multiple recurrent giant cell lesions associated with high circulating levels of parathyroid hormone-related peptide in a young adult | |
| US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
| EP1789033B1 (en) | Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders | |
| CN101091720A (en) | Health food with efficacy for preventing osteoporosis and preparation method | |
| JP4047503B2 (en) | Bone strengthening agent and food composition for bone strengthening | |
| CN1239156C (en) | Oral Solution for preventing and treating acalcerosis and its prepn process | |
| JP2948122B2 (en) | Pharmaceutical for enhancing muscle protein formation and muscle substance metabolism and method for producing the pharmaceutical | |
| CN1759851A (en) | Preparation for enriching calcium, and preparation method | |
| TW460285B (en) | A process for preparing calcium containing composition with high oral bioavailability | |
| CN1153634A (en) | Medicine for prevention and treatment of calcium deficiency and its prepn | |
| RU2246303C2 (en) | Method for pharmacological correction of calcium deficiency in patients with osteoporosis | |
| CN114711432A (en) | Water-soluble calcium and preparation method thereof, calcium agent and application of water-soluble calcium | |
| Zhang et al. | Discussion on the mechanism of the calcium absorption in the human body | |
| RU2205648C1 (en) | "calcisan" composition for prophylaxis and maintenance therapy in case of gastro-intestinal diseases | |
| WO2022006649A1 (en) | Method for producing chelated mineral concentrates with soy amino acids and/or proteins, and said product | |
| CN1123297C (en) | Production method of zinc-rich pig blood powder | |
| JPH0775526A (en) | Calcium-containing composition excellent in absorbability, production of the same composition, healthy food containing the same composition and medicine containing the same composition | |
| CN1273124C (en) | Medicinal composition containing calcium and iron elements | |
| CN104687041B (en) | Calcium absorption accelerant and calcium supplement containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |